The Effectiveness of Afatinib in a Patient with Advanced Lung Adenocarcinoma Harboring Rare G719X and S768I Mutations

The uncommon mutations in the EGFR (the epithelial growth factor receptor) gene include a heterogeneous group of genomic alterations within exons 18-21. The clinical response of patients with such mutations to EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment, however, remains unclear. We herein r...

Descripción completa

Detalles Bibliográficos
Autores principales: Watanabe, Masahiro, Oizumi, Satoshi, Kiuchi, Shizuka, Yamada, Noriyuki, Yokouchi, Hiroshi, Fukumoto, Shinichi, Harada, Masao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5919859/
https://www.ncbi.nlm.nih.gov/pubmed/29225262
http://dx.doi.org/10.2169/internalmedicine.9565-17
_version_ 1783317712941875200
author Watanabe, Masahiro
Oizumi, Satoshi
Kiuchi, Shizuka
Yamada, Noriyuki
Yokouchi, Hiroshi
Fukumoto, Shinichi
Harada, Masao
author_facet Watanabe, Masahiro
Oizumi, Satoshi
Kiuchi, Shizuka
Yamada, Noriyuki
Yokouchi, Hiroshi
Fukumoto, Shinichi
Harada, Masao
author_sort Watanabe, Masahiro
collection PubMed
description The uncommon mutations in the EGFR (the epithelial growth factor receptor) gene include a heterogeneous group of genomic alterations within exons 18-21. The clinical response of patients with such mutations to EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment, however, remains unclear. We herein report a case of advanced lung adenocarcinoma harboring complex exon 18 G719X (Gly719Xaa) and exon 20 S768I (Ser768Ile) mutations. The patient started to receive afatinib and has exhibited good response without progression for 12 months. Second-generation EGFR-TKIs might be an optimal treatment option for non-small cell lung cancers harboring these types of rare EGFR mutation.
format Online
Article
Text
id pubmed-5919859
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-59198592018-04-27 The Effectiveness of Afatinib in a Patient with Advanced Lung Adenocarcinoma Harboring Rare G719X and S768I Mutations Watanabe, Masahiro Oizumi, Satoshi Kiuchi, Shizuka Yamada, Noriyuki Yokouchi, Hiroshi Fukumoto, Shinichi Harada, Masao Intern Med Case Report The uncommon mutations in the EGFR (the epithelial growth factor receptor) gene include a heterogeneous group of genomic alterations within exons 18-21. The clinical response of patients with such mutations to EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment, however, remains unclear. We herein report a case of advanced lung adenocarcinoma harboring complex exon 18 G719X (Gly719Xaa) and exon 20 S768I (Ser768Ile) mutations. The patient started to receive afatinib and has exhibited good response without progression for 12 months. Second-generation EGFR-TKIs might be an optimal treatment option for non-small cell lung cancers harboring these types of rare EGFR mutation. The Japanese Society of Internal Medicine 2017-12-08 2018-04-01 /pmc/articles/PMC5919859/ /pubmed/29225262 http://dx.doi.org/10.2169/internalmedicine.9565-17 Text en Copyright © 2018 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Watanabe, Masahiro
Oizumi, Satoshi
Kiuchi, Shizuka
Yamada, Noriyuki
Yokouchi, Hiroshi
Fukumoto, Shinichi
Harada, Masao
The Effectiveness of Afatinib in a Patient with Advanced Lung Adenocarcinoma Harboring Rare G719X and S768I Mutations
title The Effectiveness of Afatinib in a Patient with Advanced Lung Adenocarcinoma Harboring Rare G719X and S768I Mutations
title_full The Effectiveness of Afatinib in a Patient with Advanced Lung Adenocarcinoma Harboring Rare G719X and S768I Mutations
title_fullStr The Effectiveness of Afatinib in a Patient with Advanced Lung Adenocarcinoma Harboring Rare G719X and S768I Mutations
title_full_unstemmed The Effectiveness of Afatinib in a Patient with Advanced Lung Adenocarcinoma Harboring Rare G719X and S768I Mutations
title_short The Effectiveness of Afatinib in a Patient with Advanced Lung Adenocarcinoma Harboring Rare G719X and S768I Mutations
title_sort effectiveness of afatinib in a patient with advanced lung adenocarcinoma harboring rare g719x and s768i mutations
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5919859/
https://www.ncbi.nlm.nih.gov/pubmed/29225262
http://dx.doi.org/10.2169/internalmedicine.9565-17
work_keys_str_mv AT watanabemasahiro theeffectivenessofafatinibinapatientwithadvancedlungadenocarcinomaharboringrareg719xands768imutations
AT oizumisatoshi theeffectivenessofafatinibinapatientwithadvancedlungadenocarcinomaharboringrareg719xands768imutations
AT kiuchishizuka theeffectivenessofafatinibinapatientwithadvancedlungadenocarcinomaharboringrareg719xands768imutations
AT yamadanoriyuki theeffectivenessofafatinibinapatientwithadvancedlungadenocarcinomaharboringrareg719xands768imutations
AT yokouchihiroshi theeffectivenessofafatinibinapatientwithadvancedlungadenocarcinomaharboringrareg719xands768imutations
AT fukumotoshinichi theeffectivenessofafatinibinapatientwithadvancedlungadenocarcinomaharboringrareg719xands768imutations
AT haradamasao theeffectivenessofafatinibinapatientwithadvancedlungadenocarcinomaharboringrareg719xands768imutations
AT watanabemasahiro effectivenessofafatinibinapatientwithadvancedlungadenocarcinomaharboringrareg719xands768imutations
AT oizumisatoshi effectivenessofafatinibinapatientwithadvancedlungadenocarcinomaharboringrareg719xands768imutations
AT kiuchishizuka effectivenessofafatinibinapatientwithadvancedlungadenocarcinomaharboringrareg719xands768imutations
AT yamadanoriyuki effectivenessofafatinibinapatientwithadvancedlungadenocarcinomaharboringrareg719xands768imutations
AT yokouchihiroshi effectivenessofafatinibinapatientwithadvancedlungadenocarcinomaharboringrareg719xands768imutations
AT fukumotoshinichi effectivenessofafatinibinapatientwithadvancedlungadenocarcinomaharboringrareg719xands768imutations
AT haradamasao effectivenessofafatinibinapatientwithadvancedlungadenocarcinomaharboringrareg719xands768imutations

Ejemplares similares